Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejmg.2020.104098 http://scihub22266oqcxt.onion/10.1016/j.ejmg.2020.104098 33186762!7654320!33186762     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Med+Genet 2020 ; 63 (12): 104098 Nephropedia Template TP {{tp|p=33186762|t=2020. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic |pdf=|usr=}}{{33186762}} gab.com Text Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic JO: Eur J Med Genet http://www.kidney.de/pget.php?&tw=1&pmid=33186762 #FOAvip INTRODUCTION: Mainstreamed genetic testing (MGT) obviates the need for a cancer genetics consultation, since trained oncologists (O) and gynaecologists (G) provide counseling, prescribe testing and deliver results. We report results from our MGT program and emphasize its utility during the COVID-19 lockdown, when cancer genetics clinics had suspended their activity. METHODS: An MGT pathway for breast and ovarian cancer (BC/OC) patients was established in Jan-2018 between the Assistance Publique - Hopitaux de Paris.Sorbonne Universite Cancer Genetics team and the Oncology/Gynecology departments at one teaching and two regional hospitals. Trained O + G evaluated patients with the Manchester Scoring System. A 12-point threshold was recommended for testing. Next-generation sequencing of BRCA1, BRCA2, PALB2, RAD51C and RAD51D was performed. Results were delivered to the patient by O/G. Pathogenic variants (PV) carriers were referred to the genetics clinic. Results are reported for the 2nd-Jan-2018 to 1st-June-2020 period. That includes the eight-week COVID-19 lockdown and three-week de-confinement phase 1. RESULTS: Results were available for 231/234 patients. Twenty-eight (12.1%) carried a PV. Of the 27 patients tested during the COVID-19 period, three carried a PV, two in BRCA1 and one in RAD51C. The clinical impact was immediate for the two BRCA1 BC cases undergoing neo-adjuvant chemotherapy, since double mastectomy and salpingo-oophorectomy will now be performed using two-step strategies. CONCLUSIONS: MGT guaranteed care continuity in BC/OC patients during the critical phases of the COVID-19 pandemic, with immediate implications for PV carriers. More broadly, we report for the first time the successful implementation of MGT in France. Twit Text FOAVip Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic ????Eur J Med Genet http://www.kidney.de/pget.php?&tw=1&pmid=33186762 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33186762 #FOAvip English Wikipedia <ref>{{Cite pmid|33186762}}</ref> Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic #MMPMID33186762 Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F Eur J Med Genet 2020[Dec]; 63 (12): 104098 PMID33186762show ga INTRODUCTION: Mainstreamed genetic testing (MGT) obviates the need for a cancer genetics consultation, since trained oncologists (O) and gynaecologists (G) provide counseling, prescribe testing and deliver results. We report results from our MGT program and emphasize its utility during the COVID-19 lockdown, when cancer genetics clinics had suspended their activity. METHODS: An MGT pathway for breast and ovarian cancer (BC/OC) patients was established in Jan-2018 between the Assistance Publique - Hopitaux de Paris.Sorbonne Universite Cancer Genetics team and the Oncology/Gynecology departments at one teaching and two regional hospitals. Trained O + G evaluated patients with the Manchester Scoring System. A 12-point threshold was recommended for testing. Next-generation sequencing of BRCA1, BRCA2, PALB2, RAD51C and RAD51D was performed. Results were delivered to the patient by O/G. Pathogenic variants (PV) carriers were referred to the genetics clinic. Results are reported for the 2nd-Jan-2018 to 1st-June-2020 period. That includes the eight-week COVID-19 lockdown and three-week de-confinement phase 1. RESULTS: Results were available for 231/234 patients. Twenty-eight (12.1%) carried a PV. Of the 27 patients tested during the COVID-19 period, three carried a PV, two in BRCA1 and one in RAD51C. The clinical impact was immediate for the two BRCA1 BC cases undergoing neo-adjuvant chemotherapy, since double mastectomy and salpingo-oophorectomy will now be performed using two-step strategies. CONCLUSIONS: MGT guaranteed care continuity in BC/OC patients during the critical phases of the COVID-19 pandemic, with immediate implications for PV carriers. More broadly, we report for the first time the successful implementation of MGT in France. |*Genetic Testing[MESH] |*Pandemics[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |BRCA1 Protein/genetics[MESH] |BRCA2 Protein/genetics[MESH] |Breast Neoplasms/drug therapy/*genetics/surgery[MESH] |COVID-19/*epidemiology[MESH] |DNA-Binding Proteins/genetics[MESH] |Fanconi Anemia Complementation Group N Protein/genetics[MESH] |Female[MESH] |Genetic Counseling[MESH] |Genetic Predisposition to Disease[MESH] |Hereditary Breast and Ovarian Cancer Syndrome/*genetics[MESH] |High-Throughput Nucleotide Sequencing[MESH] |Humans[MESH] |Male[MESH] |Mastectomy[MESH] |Middle Aged[MESH] |Neoadjuvant Therapy[MESH] |Ovarian Neoplasms/drug therapy/*genetics/surgery[MESH] |Paris/epidemiology[MESH] |Salpingo-oophorectomy[MESH]Utility of a mainstreamed genetic testing pathway in breast and ovaria(epmc).pdf DeepDyve Pubget Overpricing